International Biotechnol... Share Discussion Threads

[davebowler] 21/7/2010 16:37

The Manager of BIOG's views;

biotech will be a net beneficiary of healthcare reform; the regulatory environment will continue to improve; M&A activity will continue at a steady pace; and, in P/E terms, biotech valuations are at 15-year lows. As such, the outlook for the sector is positive.

[davebowler] 08/6/2010 13:55

THE BIOTECH GROWTH TRUST PLC is on a 4% discount to assets yet this is at a 18% discount -crazy!

[davebowler] 30/4/2010 11:09

The Board of International Biotechnology Trust plc (the "Company") notes that Gold Medal Acquisitions UK Limited has made a bid for the AIM listed company Fulcrum Pharma Plc (Ticker: LON:FUL). The Company has committed up to £1.3m to the funding of a new investment in Gold Medal Acquisitions UK limited were it to be successful in its bid.

[davebowler] 17/4/2010 20:19

From the Times;
IBT

Vectura, Vernalis, and now Antisoma - the roster of British biotechnology stocks to have disappointed investors grows by the day.

Which is why International Biotechnology Trust, a London-listed closed-end fund, may appeal to those seeking a lower-risk entry to this high-risk niche. First, it provides diversification, spreading its bets between 58 companies, rather than one. Second, only 10 per cent of IBT's funds are invested in the perenially underperforming UK - much of them in Shire, a long-term holding. Instead, it has 80 per cent of its capital in the US, where it is exposed to both the sector's stalwarts, such as Amgen and Genzyme, and up-and-coming mid-caps that might pass the amateur by - Micromet, the cancer specialist that is its biggest holding, being a prime example. Finally, through its relationship with SV Life Science, IBT has 20 per cent of its £110 million portfolio tied up in unquoted companies, which private investors are unable to access.

Yesterday's first-half figures show IBT continues to deliver increases in net asset value (NAV) - up 8 per cent to 164p in the six months to March 31. Helped by clarity over US healthcare reforms, and a Japanese hostile bid for OSI, one of its holdings, NAV has since risen further - to 178p.

The case from here is that half a dozen of IBT's big American stocks, such as Celgene and Vertex, will report important trial results in 2010. Meanwhile, its unquoted portfolio is now of a suffient maturity to start providing an exit. Above all, American biotech stocks, at 14 times earnings, remain inexpensive - even more so given that, at 139¾p, IBT sits at a 22 per cent discount to NAV, and will benefit from sterling weakness. Buy.

[shiptoshaw] 24/3/2010 13:41

still trading 40 odd p below nav

[davebowler] 03/3/2010 13:11

This thread includes charts etc

[foster] 13/11/2008 12:09

romi2nikki1...........It is a puzzle why the IBT share price has not responded to the recent increase in NAV. The company has declared an objective of maintaining the discount at no greater than 8%. To that end, they have recently bought back 5% of the shares into treasury at 20% discount. In addition, they do not hedge currency. Ongoing depreciation of GBP against USD is offsetting significantly any fall in underlying US asset values.
Two good reasons to expect a correction.

[romi2nikki1] 12/11/2008 20:48

Discount seems wide on historical basis, and considerably wider than discount on the Frostrow Trust ( biog). Biog much more volatile range, whereas a steady widening IBT. Consider that it is because IBT holds much more unquoted, but as long been the case. Excellent detail on IBT site, much more detail on pipeline progression and cashburn of holdings.

[gurp] 23/1/2007 21:33

see

seems A shares incur a buying fee, B shares a selling fee & C shares an ongoing charge - which I'd have thought applied to most IT's

prospectus
esp end page 2, & 3

take it the C shares will be invested separately then the portfolios combined in ratio to the NAV's achieved

can see the point of the offer to raise cash

DYOR & NAI!!

[21up] 16/1/2007 20:34

Can anybody help me .What is a C share?

[gurp] 13/11/2006 09:34

unfortunately now at a slight premium to nav, small bios in vogue with large pharmas looking for new products

[21up] 11/10/2006 17:56

Information needed.Is MW talking about IBT?Thanks

[duden1] 10/10/2006 14:15

Still going up. Was going to dump this one, but now hanging on!

[planetgong] 04/10/2006 21:13

I've noticed that whilst my miners and oils are bombing all my biotechs are ticking up from a very bad slump. I reckon IBT is pretty safe - probably won't be spectacular either up or down.

cheerio pg

[21up] 04/10/2006 20:29

My daughter's wedding has been & gone,got a few quid spare,is IBT a good bet?